David A. Siegel Nuvalent, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 9,000 shares of NUVL stock, worth $757,980. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,000
Previous 101,300
91.12%
Holding current value
$757,980
Previous $7.18 Million
90.45%
% of portfolio
0.0%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding NUVL
# of Institutions
225Shares Held
59.8MCall Options Held
191KPut Options Held
306K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.52 Billion31.57% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$444 Million18.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$381 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$255 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$151 Million0.02% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.62B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...